Ensuring Sufficient Trough Plasma Concentrations for Broad-Spectrum Beta-Lactam Antibiotics in Children With Malignancies: Beware of Augmented Renal Clearance!

Pascal André, Léonore Diezi, Kim Dao, Pierre Alex Crisinel, Laura E Rothuizen, Haithem Chtioui, Laurent Arthur Decosterd, Manuel Diezi, Sandra Asner, Thierry Buclin, Pascal André, Léonore Diezi, Kim Dao, Pierre Alex Crisinel, Laura E Rothuizen, Haithem Chtioui, Laurent Arthur Decosterd, Manuel Diezi, Sandra Asner, Thierry Buclin

Abstract

Introduction: Broad-spectrum beta-lactams are commonly prescribed for empirical or selective treatment of bacterial infections in children with malignancies. In the immunocompromised, appropriate concentration exposure is crucial to ensure antimicrobial efficacy. Augmented renal clearance (ARC) is increasingly recognized in this population, and raises concern for unmet concentration targets. We conducted a retrospective evaluation of meropenem and piperacillin exposure in our hospital's pediatric hematology-oncology patients. Materials and Methods: We compared trough levels of meropenem and piperacillin in a cohort of unselected pediatric hematology-oncology patients stratified based on their estimated renal function as decreased, normal or with ARC, and on their neutrophil count. Results: Thirty-two children provided a total of 51 meropenem and 76 piperacillin samples. On standard intermittent intravenous regimen, 67% of all trough plasma concentrations were below targeted concentrations. In neutropenic children with bacterial infection, all meropenem and 60% of piperacillin levels were below target. Nearly two-thirds of total samples came from children with ARC. In these patients, antimicrobial exposure was insufficient in 85% of cases (compared to 36% in the decreased or normal renal function groups), despite a dosage sometimes exceeding the maximum recommended daily dose. Under continuous infusion of piperacillin, only 8% of plasma levels were insufficient. Discussion: Intermittent administration of meropenem and piperacillin often fails to ensure sufficient concentration exposure in children treated for malignancies, even at maximal recommended daily dosage. This can in part be attributed to ARC. We recommend thorough assessment of renal function, resolute dosage adjustment, continuous infusion whenever possible and systematic therapeutic drug monitoring.

Keywords: augmented renal clearance; beta-lactams; cancer; child; kidney function tests; meropenem; neoplasms; piperacillin.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 André, Diezi, Dao, Crisinel, Rothuizen, Chtioui, Decosterd, Diezi, Asner and Buclin.

Figures

Figure 1
Figure 1
First trough concentration values of MER and PIP obtained during 25, respectively, 23 treatment cycles in a series of hospitalized pediatric hematology-oncology patients, according to the total daily dosage administered as intermittent short infusions. Shaded range is the targeted concentration interval for common bacteria. Symbols represent the patients' creatinine clearance according to the Schwartz formula: ◯ normal (80–160 mL/min/1.73 m2). ▽ decreased (2). ▴ augmented (>160 mL/min/1.73 m2).
Figure 2
Figure 2
First (black) and subsequent (grey) trough concentration values of MER and PIP obtained during 25, respectively, 23 treatment cycles in a series of hospitalized pediatric hematology-oncology patients, according to the total daily dosage administered as intermittent short infusions. Measurements in individual patients are connected. Shaded range is the targeted concentration interval for common bacteria. Symbols represent the patients' creatinine clearance according to the Schwartz formula: ◯ normal (80–160 mL/min/1.73 m2). ▽ decreased (2). ▴ augmented (>160 mL/min/1.73 m2).

References

    1. Lam CG, Howard SC, Bouffet E, Pritchard-Jones K. Science and health for all children with cancer. Science. (2019) 363:1182–6. 10.1126/science.aaw4892
    1. Erdmann F, Frederiksen LE, Bonaventure A, Mader L, Hasle H, Robison LL, et al. . Childhood cancer: survival, treatment modalities, late effects and improvements over time. Cancer Epidemiol. (2021) 71(Pt. B):101733. 10.1016/j.canep.2020.101733
    1. Centers for Disease Control Prevention National Center for Health Statistics. Underlying Cause of Death 1999-2019 on CDC WONDER Online Database, Released in 2020. Data Are From the Multiple Cause of Death Files, 1999-2019, as Compiled From Data Provided by the 57 Vital Statistics Jurisdictions Through the Vital Statistics Cooperative Program. (2020). Available online at: (accessed October 27, 2021).
    1. Institut National de la Statistique et des Etudes Economiques (INSEE). i. Données Annuelles de 2000 à 2016. ed (2019). Available online at: (accessed October 27, 2021).
    1. Inaba H, Pei D, Wolf J, Howard SC, Hayden RT, Go M, et al. . Infection-related complications during treatment for childhood acute lymphoblastic leukemia. Ann Oncol. (2017) 28:386–92. 10.1093/annonc/mdw557
    1. Christensen MS, Heyman M, Mottonen M, Zeller B, Jonmundsson G, Hasle H, et al. . Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001. Br J Haematol. (2005) 131:50–8. 10.1111/j.1365-2141.2005.05736.x
    1. O'Connor D, Bate J, Wade R, Clack R, Dhir S, Hough R, et al. . Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood. (2014) 124:1056–61. 10.1182/blood-2014-03-560847
    1. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. (2004) 22:4384–93. 10.1200/JCO.2004.01.191
    1. Zajac-Spychala O, Wachowiak J, Szmydki-Baran A, Hutnik L, Salamonowicz M, Matysiak M, et al. . Infectious complications in children treated for hodgkin and non-hodgkin lymphomas in polish pediatric leukemia/lymphoma study group: incidence, epidemiology and etiology. Leuk Lymphoma. (2019) 60:124–32. 10.1080/10428194.2018.1466293
    1. Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. . International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. (2017) 18:719–31.
    1. Auletta JJ, O'Riordan MA, Nieder ML. Infections in children with cancer: a continued need for the comprehensive physical examination. J Pediatr Hematol Oncol. (1999) 21:501–8. 10.1097/00043426-199911000-00010
    1. Celkan T, Ozkan A, Apak H, Diren S, Can G, Yuksel L, et al. . Bacteremia in childhood cancer. J Trop Pediatr. (2002) 48:373–7. 10.1093/tropej/48.6.373
    1. Cojutti PG, Candoni A, Lazzarotto D, Fili C, Zannier M, Fanin R, et al. . Population pharmacokinetics of continuous-infusion meropenem in febrile neutropenic patients with hematologic malignancies: dosing strategies for optimizing empirical treatment against Enterobacterales and P. aeruginosa. Pharmaceutics. (2020) 12:785. 10.3390/pharmaceutics12090785
    1. Sime FB, Roberts MS, Tiong IS, Gardner JH, Lehman S, Peake SL, et al. . Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial. J Antimicrob Chemother. (2015) 70:2369–75. 10.1093/jac/dkv123
    1. Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, et al. . Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother. (2013) 57:6165–70. 10.1128/AAC.00951-13
    1. Deshayes S, Coquerel A, Verdon R. Neurological adverse effects attributable to beta-lactam antibiotics: a literature review. Drug Saf. (2017) 40:1171–98. 10.1007/s40264-017-0578-2
    1. Roger C, Louart B. Beta-lactams toxicity in the intensive care unit: an underestimated collateral damage? Microorganisms. (2021) 9:1505. 10.3390/microorganisms9071505
    1. Dhont E, Van Der Heggen T, De Jaeger A, Vande Walle J, De Paepe P, De Cock PA. Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients? Pediatr Nephrol. (2020) 35:25–39. 10.1007/s00467-018-4120-2
    1. Udy AA, Jarrett P, Stuart J, Lassig-Smith M, Starr T, Dunlop R, et al. . Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds. Crit Care. (2014) 18:657. 10.1186/s13054-014-0657-z
    1. Mahmoud SH, Shen C. Augmented renal clearance in critical illness: an important consideration in drug dosing. Pharmaceutics. (2017) 9:36. 10.3390/pharmaceutics9030036
    1. Cook AM, Hatton-Kolpek J. Augmented renal clearance. Pharmacotherapy. (2019) 39:346–54. 10.1002/phar.2231
    1. Hjorth L, Wiebe T, Karpman D. Hyperfiltration evaluated by glomerular filtration rate at diagnosis in children with cancer. Pediatr Blood Cancer. (2011) 56:762–6. 10.1002/pbc.22971
    1. Kwatra NS, Meany HJ, Ghelani SJ, Zahavi D, Pandya N, Majd M. Glomerular hyperfiltration in children with cancer: prevalence and a hypothesis. Pediatr Radiol. (2017) 47:221–6. 10.1007/s00247-016-3733-5
    1. Udy AA, De Waele JJ, Lipman J. Augmented renal clearance and therapeutic monitoring of beta-lactams. Int J Antimicrob Agents. (2015) 45:331–3. 10.1016/j.ijantimicag.2014.12.020
    1. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, et al. . Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. (2012) 142:30–9. 10.1378/chest.11-1671
    1. Saffioti C, Mesini A, Barco S, Cangemi G, Bandettini R, Castagnola E. Piperacillin-tazobactam concentration target attainment in children with cancer. Pediatr Blood Cancer. (2019) 66:e27882. 10.1002/pbc.27882
    1. Carrie C, Petit L, d'Houdain N, Sauvage N, Cottenceau V, Lafitte M, et al. . Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of beta-lactams administered by continuous infusion: a prospective observational study. Int J Antimicrob Agents. (2018) 51:443–9. 10.1016/j.ijantimicag.2017.11.013
    1. Decosterd LA, Mercier T, Ternon B, Cruchon S, Guignard N, Lahrichi S, et al. . Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections. J Chromatogr B Analyt Technol Biomed Life Sci. (2020) 1157:122160. 10.1016/j.jchromb.2020.122160
    1. Robatel C, Decosterd LA, Biollaz J, Eckert P, Schaller MD, Buclin T. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol. (2003) 43:1329–40. 10.1177/0091270003260286
    1. EUCAST. Data From the EUCAST MIC Distribution Website. (2021). Available online at: (accessed October 27, 2021).
    1. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. (1976) 58:259–63. 10.1542/peds.58.2.259
    1. Hirai K, Ihara S, Kinae A, Ikegaya K, Suzuki M, Hirano K, et al. . Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance. Ther Drug Monit. (2016) 38:393–7. 10.1097/FTD.0000000000000270
    1. Group ET, Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, et al. . Strict blood-pressure control and progression of renal failure in children. N Engl J Med. (2009) 361:1639–50. 10.1056/NEJMoa0902066
    1. Taketomo CK, Hodding JH, Kraus DM. Pediatric & Neonatal Dosage Handbook: A Universal Resource for Clinicians Treating Pediatric and Neonatal Patients. 21st ed. Hudson, OH: Lexi-Comp (2014-2015).
    1. SwissPedDose T. Database of Harmonized Dosage Recommendations for Pediatric Pharmacotherapy (2021). Available online at: (accessed October 27, 2021).
    1. Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CM, et al. . Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins. Pediatr Pulmonol. (2013) 48:107–22. 10.1002/ppul.22669
    1. Cielecka-Piontek J, Michalska K, Zalewski P, Jelinska A. Recent advances in stability studies of carbapenems. Curr Pharmaceut Anal. (2011) 7:213–27. 10.2174/157341211797457989
    1. Carlier M, Carrette S, Roberts JA, Stove V, Verstraete A, Hoste E, et al. . Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care. (2013) 17:R84. 10.1186/cc12705
    1. Curth HM, Pelc A, Kutting F, Steffen HM. Augmented renal vancomycin clearance in cancer patients: a case report and review of the literature. Oncol Res Treat. (2015) 38:182–4. 10.1159/000377652
    1. Maarbjerg SF, Thorsted A, Kristoffersson A, Friberg LE, Nielsen EI, Wang M, et al. . Piperacillin pharmacokinetics and target attainment in children with cancer and fever: can we optimize our dosing strategy? Pediatr Blood Cancer. (2019) 66:e27654. 10.1002/pbc.27654
    1. Sridharan K, Al-Daylami A, Ajjawi R, Ajooz HAA. Vancomycin use in a paediatric intensive care unit of a tertiary care hospital. Paediatr Drugs. (2019) 21:303–12. 10.1007/s40272-019-00343-9
    1. Van Der Heggen T, Dhont E, Peperstraete H, Delanghe JR, Vande Walle J, De Paepe P, et al. . Augmented renal clearance: a common condition in critically ill children. Pediatr Nephrol. (2019) 34:1099–106. 10.1007/s00467-019-04205-x
    1. Skinner R, Cole M, Pearson AD, Keir MJ, Price L, Wyllie RA, et al. . Inaccuracy of glomerular filtration rate estimation from height/plasma creatinine ratio. Arch Dis Child. (1994) 70:387–90. 10.1136/adc.70.5.387
    1. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. (1998) 27:10–22. 10.1086/514622
    1. Huttner A, Harbarth S, Hope WW, Lipman J, Roberts JA. Therapeutic drug monitoring of the beta-lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother. (2015) 70:3178–83. 10.1093/jac/dkv201
    1. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis. (2008) 47(Suppl. 1):S32–40. 10.1086/590064
    1. Frei CR, Burgess DS. Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002. Clin Ther. (2008) 30:2335–41. 10.1016/j.clinthera.2008.12.009

Source: PubMed

3
Abonner